A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker

被引：210
作者：
Khoja, L. [1 ,2 ,3 ]
Backen, A.
Sloane, R.
Menasce, L. [2 ]
Ryder, D. [2 ]
Krebs, M. [1 ,2 ,3 ]
Board, R. [2 ]
Clack, G. [4 ]
Hughes, A. [4 ]
Blackhall, F. [1 ,2 ,3 ]
Valle, J. W. [1 ,2 ,3 ]
Dive, C. [1 ,3 ]
机构：
[1] Univ Manchester, Manchester Canc Res Ctr, Sch Canc & Enabling Sci, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester M20 4BX, Lancs, England
[3] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] AstraZeneca, Alderley Pk SK10 4TG, Cheshire, England
来源：
BRITISH JOURNAL OF CANCER | 2012年 / 106卷 / 03期
关键词：
circulating tumour cells; circulating tumour microemboli; pancreatic cancer; ISET; CellSearch; tumour biopsy; PHASE-III TRIAL; PERIPHERAL-BLOOD; GEMCITABINE; SURVIVAL; THERAPY; PREDICT; SIZE; ADENOCARCINOMA; PROGRESSION; METASTASIS;
D O I：
10.1038/bjc.2011.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND: Obtaining tissue for pancreatic carcinoma diagnosis and biomarker assessment to aid drug development is challenging. Circulating tumour cells (CTCs) may represent a potential biomarker to address these unmet needs. We compared prospectively the utility of two platforms for CTC enumeration and characterisation in pancreatic cancer patients in a pilot exploratory study. PATIENTS AND METHODS: Blood samples were obtained prospectively from 54 consenting patients and analysed by CellSearch and isolation by size of epithelial tumour cells (ISET). CellSearch exploits immunomagnetic capture of CTCs-expressing epithelial markers, whereas ISET is a marker independent, blood filtration device. Circulating tumour cell expression of epithelial and mesenchymal markers was assessed to explore any discrepancy in CTC number between the two platforms. RESULTS: ISET detected CTCs in more patients than CellSearch (93% vs 40%) and in higher numbers (median CTCs/7.5 ml, 9 (range 0-240) vs 0 (range 0-144)). Heterogeneity observed for epithelial cell adhesion molecule, pan-cytokeratin (CK), E-Cadherin, Vimentin and CK 7 expression in CTCs may account for discrepancy in CTC number between platforms. CONCLUSION: ISET detects more CTCs than CellSearch and offers flexible CTC characterisation with potential to investigate CTC biology and develop biomarkers for pancreatic cancer patient management. British Journal of Cancer (2012) 106, 508-516. doi: 10.1038/bjc.2011.545 www.bjcancer.com Published online 20 December 2011 (C) 2012 Cancer Research UK
引用
收藏
页码：508 / 516
页数：9
相关论文
共 42 条
[1]   Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis [J].
Al-Mehdi, AB ;
Tozawa, K ;
Fisher, AB ;
Shientag, L ;
Lee, A ;
Muschel, RJ .
NATURE MEDICINE, 2000, 6 (01) :100-102
[2]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[3]  
[Anonymous], ASCO M ABSTR
[4]   EpCAM (CD326) finding its role in cancer [J].
Baeuerle, P. A. ;
Gires, O. .
BRITISH JOURNAL OF CANCER, 2007, 96 (03) :417-423
[5]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[6]   Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer [J].
Cohen, Steven J. ;
Punt, Cornelis J. A. ;
Iannotti, Nicholas ;
Saidman, Bruce H. ;
Sabbath, Kert D. ;
Gabrail, Nashat Y. ;
Picus, Joel ;
Morse, Michael ;
Mitchell, Edith ;
Miller, M. Craig ;
Doyle, Gerald V. ;
Tissing, Henk ;
Terstappen, Leon W. M. M. ;
Meropol, Neal J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3213-3221
[7]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[8]   All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer [J].
Coumans, F. A. W. ;
Doggen, C. J. M. ;
Attard, G. ;
de Bono, J. S. ;
Terstappen, L. W. M. M. .
ANNALS OF ONCOLOGY, 2010, 21 (09) :1851-1857
[9]   Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].
Cristofanilli, M ;
Budd, GT ;
Ellis, MJ ;
Stopeck, A ;
Matera, J ;
Miller, MC ;
Reuben, JM ;
Doyle, GV ;
Allard, WJ ;
Terstappen, LWMM ;
Hayes, DF .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791
[10]   Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].
de Bono, Johann S. ;
Scher, Howard I. ;
Montgomery, R. Bruce ;
Parker, Christopher ;
Miller, M. Craig ;
Tissing, Henk ;
Doyle, Gerald V. ;
Terstappen, Leon W. W. M. ;
Pienta, Kenneth J. ;
Raghavan, Derek .
CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309
12345